$MRVI

TriLink BioTechnologies, a Maravai LifeSciences company, secured a second CleanCap patent in China, expanding its IP protection for RNA technology. The new patent covers CleanCap cap analog compounds and related pharmaceutical compositions, complementing an earlier patent on synthesis methods. The patents strengthen TriLink's position in the RNA medicines market, with applications in mRNA vaccines and therapeutics.

Analysts made several calls on Monday. Morgan Stanley upgraded Wells Fargo to overweight, citing improved balance sheet growth. Bank of America initiated Vylor with a buy rating and $78 price target. Bernstein reiterated Nvidia as outperform, highlighting its datacenter opportunity. BMO initiated nVent Electric and Vertiv as outperform, citing growth in AI infrastructure and data centers. Jefferies initiated Samsara as buy, expecting strong revenue growth.

TD Cowen initiated coverage of Maravai Lifesciences with a Buy rating and a $9 price target. The company's TriLink division recently received a new China patent for its CleanCap technology. Maravai's stock has seen a 5.33% increase over 5 days and a 143.08% rise year-to-date.

Maravai LifeSciences (MRVI) reported a Q2 net loss of $21.6M but improved adjusted EBITDA to $8.7M. The company raised its full-year adjusted EBITDA guidance to $33M-$35M. Hedge funds are increasing their holdings, while short interest stands at 9.84% of float. MRVI's valuation hinges on sustained profit improvements and patent-protected technologies.

Maravai LifeSciences' (MRVI) subsidiary TriLink BioTechnologies received a China patent for its CleanCap mRNA compounds. The patent covers CleanCap cap analog compounds, RNA molecules, and pharmaceutical compositions. This is TriLink's second CleanCap patent in China, with the first covering synthesis methods. The patents protect both manufacturing processes and molecular structures. CleanCap technology is used in COVID-19 vaccines and various mRNA therapeutic development programs.

Maravai LifeSciences Holdings (MRVI) reported 1H 2026 revenue growth of 24% and adjusted EBITDA of $29M. The company attributed this to cost reductions, new leadership, and a diversified pipeline, positioning it for future profitable growth.

Shares of BioNTech (BNTX), Moderna (MRVI), Regeneron (RGEN), and Novavax (NVAX) rose 20%, 25%, 6%, and 6% respectively after a Moderna-Merck cancer vaccine trial succeeded. Analysts expect benefits for Merck and suppliers like Repligen, Danaher, Thermo Fisher, and Maravai. TEM stock gained 2% YTD, with 8/16 analysts rating it 'Buy' or higher, and a 27% potential upside from its last close.

Maravai LifeSciences (MRVI) reported Q2 2026 revenue of $51.4 million, up 8.5% year over year, with TriLink at $34.7 million and Cygnus at $16.8 million. Adjusted EBITDA was $8.7 million, and GAAP net loss was $21.6 million. Full-year guidance: revenue $205-$215 million and adjusted EBITDA $33-$35 million.

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Second quarter 2026 total revenue up 9% from prior year SAN DIEGO, Calif., — August 6, 2026 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents a

Biotech stocks rose to 52-week highs on July 22, 2026 after positive updates. Medpace (MEDP) jumped over 77% to $677.90 on Q2 results, with GAAP net income of $121.4M and revenue up 17% to $707M. Novocure (NVCR) gained 28% to $20.55 on Q2 net revenues of $183.6M. Eton (ETON) and Maravai (MRVI) also hit highs; Advanced Biomed (ADVB) rose 36% to $20.87.